Nociceptive TRP channels in regulating cancer progression
| Channel | Tumor types | Tumor cells vs. Normal controls | Pathological function in cancer | Prognosis | Reference |
|---|---|---|---|---|---|
| TRPA1 | Breast cancer, lung cancer, pancreatic cancer, nasopharyngeal carcinoma | Over-expression | Promote cancer cell survival against chemotherapeutic agents | Unfavorable in breast cancer, lung cancer, nasopharyngeal carcinoma | [82, 89, 90] |
| TRPC1 | Breast cancer (PTEN-deficient type), lung cancer, gastric cancer, pancreatic cancer, colorectal cancer, glioblastoma | Over-expression | Promote cancer cell growth and metastasis | Unfavorable in breast cancer (PTEN-deficient type), gastric cancer | [91, 92] |
| TRPC3 | Breast cancer (triple negative type), ovarian cancer | Over-expression | Promote cancer cell growth and cancer cell survival against chemotherapeutic agents | Unfavorable in breast cancer, ovarian cancer | [40, 93] |
| TRPC5 | Breast cancer, colorectal cancer | Over-expression | Promote cancer cell survival against chemotherapeutic agents, tumor metastasis | Unfavorable in colorectal cancer | [94, 95] |
| TRPC6 | Breast cancer, hepatoma, gastric cancer, ESCC, prostate cancer, glioblastoma | Over-expression | Promote cancer cell growth and metastasis | Unfavorable in esophageal squamous cell carcinoma | [96–101] |
| TRPC7 | Lung cancer, skin sarcoma | Over-expression | Promote cancer cell growth | Not investigated | [13] |
| TRPM2 | Breast cancer, lung cancer, gastric cancer, pancreatic cancer, prostate cancer, HCC, oral cancer, glioblastoma | Over-expression, mutant type in PDAC, long non-coding RNA TRPM2-AS in HCC | Promote cancer cell growth and metastasis | Unfavorable in luminal B and TP53 wild type breast cancer, lung cancer, PDAC, HCC (Long non-coding RNA TRPM2-AS) | [45, 102–107] |
| TRPM3 | ccRCC, glioblastoma, choroid plexus papilloma | Over-expression | Promote cancer cell growth | Not investigated | [107–109] |
| TRPM8 | Breast cancer, lung cancer, gastric cancer, ESCC, pancreatic cancer, prostate cancer, HCC, esophageal cancer, glioblastoma, neuroblastoma, urinary bladder carcinoma | Over-expression | Promote cancer cell survival against chemotherapeutic agents, cancer cell growth and metastasis | Unfavorable in urinary bladder carcinoma | [110–113] |
| TRPV1 | Breast cancer, oral cancer, glioblastoma | Over-expression | Promote cancer cell growth | Unfavorable in breast cancer | [107, 114, 115] |
| TRPV2 | Breast cancer, gastric cancer, ESCC, prostate cancer, HCC, ovarian cancer, oral cancer, glioblastoma, hematological cancer, urinary bladder carcinoma | Over-expression, full-length TRPV2 (f-TRPV2) in urinary bladder carcinoma | Promote cancer cell growth and metastasis | Unfavorable in multiple myeloma, ESCC | [46, 107, 111, 116, 117] |
| TRPV3 | Breast cancer, lung cancer, oral cancer | Over-expression | Promote cancer cell growth and metastasis | Not investigated | [111, 116, 118] |
| TRPV4 | Breast cancer, gastric cancer, pancreatic cancer, HCC, colorectal cancer, oral cancer, glioblastoma | Over-expression | Promote cancer cell growth and metastasis | Unfavorable in gastric cancer | [93, 111, 116, 119–122] |
ESCC: esophageal squamous cell carcinoma; PTEN: phosphatase and Tensin Homolog deleted on Chromosome 10; PDAC: pancreatic ductal adenocarcinoma; HCC: hepatocellular carcinoma; ccRCC: clear cell renal cell carcinoma